Fig. 4.

Serial transplantation reveals impaired malignant stem cell function in mice receiving combination therapy. 3.5 × 10⁶ CD45.1⁺ BM cells from FVB/N wt recipients treated with vehicle and FVB/N Bcr-Abl recipients treated with vehicle, vehicle + IgG, NIL, and NIL+ IFX were transplanted into irradiated secondary CD45.2 FVB/N recipients. a Peripheral blood (PB) from secondary recipients for donor derived CD45.1⁺ cells was assessed by FACS 4 weeks after BMT. 6 weeks after 2nd BMT PB was analyzed by FACS for b donor derived CD45.1⁺, c c-kit⁺/CD45.1⁺, d Gr-1⁺/CD45.1⁺, and e B220⁺/CD45.1⁺ cells. (n = 3/4/4/4/4, *p < 0.05, **p < 0.01, ***p < 0.001)